CDTX
Price
$47.87
Change
-$1.46 (-2.96%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
1B
REPL
Price
$9.46
Change
+$0.01 (+0.11%)
Updated
Jun 26 closing price
Capitalization
729.24M
34 days until earnings call
Interact to see
Advertisement

CDTX vs REPL

Header iconCDTX vs REPL Comparison
Open Charts CDTX vs REPLBanner chart's image
Cidara Therapeutics
Price$47.87
Change-$1.46 (-2.96%)
Volume$25.5K
Capitalization1B
Replimune Group
Price$9.46
Change+$0.01 (+0.11%)
Volume$1.52M
Capitalization729.24M
CDTX vs REPL Comparison Chart in %
Loading...
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDTX vs. REPL commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDTX is a StrongBuy and REPL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (CDTX: $48.03 vs. REPL: $9.46)
Brand notoriety: CDTX and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDTX: 373% vs. REPL: 120%
Market capitalization -- CDTX: $1B vs. REPL: $729.24M
CDTX [@Biotechnology] is valued at $1B. REPL’s [@Biotechnology] market capitalization is $729.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.01B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDTX’s FA Score shows that 0 FA rating(s) are green whileREPL’s FA Score has 1 green FA rating(s).

  • CDTX’s FA Score: 0 green, 5 red.
  • REPL’s FA Score: 1 green, 4 red.
According to our system of comparison, REPL is a better buy in the long-term than CDTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDTX’s TA Score shows that 6 TA indicator(s) are bullish while REPL’s TA Score has 5 bullish TA indicator(s).

  • CDTX’s TA Score: 6 bullish, 4 bearish.
  • REPL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, CDTX is a better buy in the short-term than REPL.

Price Growth

CDTX (@Biotechnology) experienced а +125.39% price change this week, while REPL (@Biotechnology) price change was -0.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.59%. For the same industry, the average monthly price growth was +34.25%, and the average quarterly price growth was +14.95%.

Reported Earning Dates

CDTX is expected to report earnings on May 08, 2025.

REPL is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+3.59% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDTX($1.01B) has a higher market cap than REPL($729M). CDTX YTD gains are higher at: 78.683 vs. REPL (-21.883). CDTX has higher annual earnings (EBITDA): -192.6M vs. REPL (-235.43M). REPL has more cash in the bank: 484M vs. CDTX (168M). CDTX has less debt than REPL: CDTX (2.67M) vs REPL (76.2M). CDTX has higher revenues than REPL: CDTX (302K) vs REPL (0).
CDTXREPLCDTX / REPL
Capitalization1.01B729M138%
EBITDA-192.6M-235.43M82%
Gain YTD78.683-21.883-360%
P/E RatioN/AN/A-
Revenue302K0-
Total Cash168M484M35%
Total Debt2.67M76.2M4%
FUNDAMENTALS RATINGS
CDTX vs REPL: Fundamental Ratings
CDTX
REPL
OUTLOOK RATING
1..100
9373
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
26
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
3456
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REPL's Valuation (26) in the Biotechnology industry is somewhat better than the same rating for CDTX (85). This means that REPL’s stock grew somewhat faster than CDTX’s over the last 12 months.

REPL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CDTX (100). This means that REPL’s stock grew similarly to CDTX’s over the last 12 months.

REPL's SMR Rating (98) in the Biotechnology industry is in the same range as CDTX (100). This means that REPL’s stock grew similarly to CDTX’s over the last 12 months.

CDTX's Price Growth Rating (34) in the Biotechnology industry is in the same range as REPL (56). This means that CDTX’s stock grew similarly to REPL’s over the last 12 months.

CDTX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as REPL (100). This means that CDTX’s stock grew similarly to REPL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDTXREPL
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 21 days ago
77%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 4 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FGDTX35.75N/A
N/A
Fidelity Advisor Gold M
JMVZX32.14N/A
N/A
JPMorgan Mid Cap Value R2
ANDNX16.94N/A
N/A
AQR International Defensive Style N
PRKAX7.43N/A
N/A
PGIM Real Estate Income A
SGLYX11.04N/A
N/A
SEI Global Managed Volatility Y (SIMT)

CDTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDTX has been closely correlated with BPTSY. These tickers have moved in lockstep 92% of the time. This A.I.-generated data suggests there is a high statistical probability that if CDTX jumps, then BPTSY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDTX
1D Price
Change %
CDTX100%
-2.64%
BPTSY - CDTX
92%
Closely correlated
N/A
UNCY - CDTX
51%
Loosely correlated
-4.35%
INDP - CDTX
42%
Loosely correlated
+24.76%
REPL - CDTX
39%
Loosely correlated
+0.11%
IVVD - CDTX
36%
Loosely correlated
+13.43%
More